Literature DB >> 32915710

Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung Cancer.

Wanyuan Cui1, Chantal Cotter2, Katherina Bernadette Sreter1, Kara Heelan1, Daniel Creamer2, Tanya N Basu2, Jonathan Handy1, Sarah Walsh2, Sanjay Popat1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32915710     DOI： 10.1200/OP.20.00489

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  4 in total

1.  Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Andrew Gibson; Joshua Gardner; Jose Luis Castrejón-Flores; Carol Jolly; Benjamin Alexis Fisher; Neil Steven; Catherine Betts; Munir Pirmohamed; Xiaoli Meng; Dean John Naisbitt
Journal:  Toxicol Sci       Date:  2022-02-28       Impact factor: 4.849

2.  Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Dean J Naisbitt
Journal:  Clin Exp Allergy       Date:  2022-03-25       Impact factor: 5.401

3.  T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.

Authors:  Sean Hammond; Anna Olsson-Brown; Joshua Gardner; Paul Thomson; Serat-E Ali; Carol Jolly; Dan Carr; Lorenzo Ressel; Munir Pirmohamed; Dean Naisbitt
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

4.  Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program.

Authors:  Oliver Illini; Maximilian Johannes Hochmair; Hannah Fabikan; Christoph Weinlinger; Amanda Tufman; Aurélie Swalduz; Kristina Lamberg; Sayed M S Hashemi; Florian Huemer; Anders Vikström; Martin Wermke; Gudrun Absenger; Alfredo Addeo; Shantanu Banerji; Antonio Calles; Stephen Clarke; Massimo Di Maio; Alice Durand; Michaël Duruisseaux; Malinda Itchins; Okko-Sakari Kääränien; Florian Krenn; Eckart Laack; Adrianus Johannes de Langen; Katja Mohorcic; Georg Pall; Antonio Passaro; Gerald Prager; Achim Rittmeyer; Jeffrey Rothenstein; Michael Schumacher; Ewald Wöll; Arschang Valipour
Journal:  Ther Adv Med Oncol       Date:  2021-06-11       Impact factor: 8.168
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.